Director Jon Halbert receives 2,492 Caris Life (CAI) shares in grant

Rhea-AI Filing Summary

HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences director Jon Halbert received a grant of 2,492 shares of common stock as part of his 2025 board retainer, issued in stock instead of cash. The number of shares was based on the ten‑day average volume-weighted price through February 25, 2026 at $20.06 per share.

After this award, he directly holds 118,621 shares. An additional 625,000 shares are held indirectly through LAH Investments, Ltd., and 625,000 shares are held indirectly through the Jon and Linda Halbert Management Trust, following an in-kind distribution from Ke'Ohana Ventures, LLC. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HALBERT JON

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		2,492	A	$20.06	118,621	D
Common Stock								625,000	I	By LAH Investments, Ltd.(2)(3)
Common Stock								625,000	I	By Family Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

2. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

3. The 1,250,000 shares previously reported as held indirectly by Ke'Ohana Ventures, LLC were distributed in kind to its members. 625,000 shares were distributed to the Jon and Linda Halbert Management Trust, and 625,000 shares were distributed to LAH Investments, Ltd.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Caris Life Sciences (CAI) director Jon Halbert report on this Form 4?

Director Jon Halbert reported receiving 2,492 shares of Caris Life Sciences common stock as a stock grant for his 2025 board retainer. The filing also updates his direct and indirect share holdings, including positions held through LAH Investments, Ltd. and a family trust.

How many Caris Life Sciences (CAI) shares were granted to Jon Halbert and at what price?

Jon Halbert was granted 2,492 shares of Caris Life Sciences common stock. The shares were valued using a ten trading day average volume weighted average price of $20.06 per share, covering days through and including February 25, 2026, to convert his cash retainer into stock.

Why did Caris Life Sciences (CAI) issue shares to Jon Halbert instead of paying cash?

The shares were issued in lieu of cash compensation for Jon Halbert’s 2025 board retainer fees. The company determined the number of shares by dividing the earned cash retainer by the ten-day average volume weighted price per share through February 25, 2026.

What are Jon Halbert’s indirect holdings of Caris Life Sciences (CAI) shares?

The filing shows 625,000 shares held indirectly through LAH Investments, Ltd. and 625,000 shares held indirectly through the Jon and Linda Halbert Management Trust. These indirect positions reflect an in-kind distribution from Ke'Ohana Ventures, LLC to its members.

What does the Ke'Ohana Ventures, LLC distribution mean for Caris Life Sciences (CAI) ownership?

Previously, 1,250,000 shares were reported as indirectly held by Ke'Ohana Ventures, LLC. These were distributed in kind: 625,000 shares to the Jon and Linda Halbert Management Trust and 625,000 shares to LAH Investments, Ltd., reallocating but not changing the total share count involved.

What does it mean that Jon Halbert disclaims beneficial ownership of some Caris Life Sciences (CAI) shares?

He states he disclaims beneficial ownership of certain indirectly held shares except to the extent of his pecuniary interest. This indicates he does not claim full economic or control rights over all such shares beyond his direct financial stake.